Passage Bio (PASG) jumps 19% in its trading debut after its upsized IPO priced at $18 per share, the top end of its expected range $16-$18.
The offering was boosted to 12M shares of common
stock (plus 1.8M-share greenshoe option) from the 7.4M shares offering
contemplated in its IPO prospectus.
Proceeds use: To fund clinical development of therapies for rare, monogenic central nervous system disorders.
https://seekingalpha.com/news/3547132-passage-bio-shoots-up-19-in-trading-debut
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.